Business
Placing
Placing.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n10 May 2010\n\n Scancell Holdings Plc \n\n (the \"Company\") \n\n Placing \n\nScancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer\nvaccines, announces it has raised approximately £24,000 (before expenses) by\nway of a placing of 53,333 New Ordinary Shares of 0.1p each (`Placing Shares')\nat a price of 45p (the `Placing') with Wilton International Marketing Limited.\n\nAdmission and commencement of dealings in the New Ordinary Shares to be issued\nunder the Placing are expected to take place at 8.00 a.m. on 11 May 2010. There\nwill be a total of 15,926,659 Ordinary Shares in issue following Admission of\nthe Placing Shares.\n\nThe Directors of the issuer accept responsibility for this announcement.\n\n -ENDS- \n\nFor Further Information:\n\nDavid Evans Scancell Holdings Plc + 44 774 008 4452 \n \nKirsty Corcoran/John Bick Hansard Communications + 44 207 245 1100 \n \nRoss Andrews / Tom Rowley Zeus Capital + 44 161 831 1512 \n\nAbout Scancell:\n\nScancell is developing novel therapeutic vaccines for the treatment of cancer\nand infectious diseases based on its groundbreaking ImmunoBody® technology\nplatform. Scancell's first cancer vaccine SCIB1 is being developed for the\ntreatment of melanoma and is expected to enter clinical trials in 2010.\n\nTreating cancer by vaccination allows small non-toxic doses of a vaccine to be\nadministered to a patient, stimulating an immune response. Effective cancer\nvaccines need to target dendritic cells to stimulate both parts of the cellular\nimmune system; the helper cell system where inflammation is stimulated at the\ntumour site; and the cytotoxic T-lymphocyte or CTL response where immune system\ncells are primed to recognise and kill specific cells.\n\nA limitation of many cancer vaccines currently in development is that they\ncannot specifically target dendritic cells in vivo. Several groups have\ndemonstrated successful vaccination by growing dendritic cells ex vivo, pulsing\nthem with tumour antigens and re-infusing them. However, this procedure is\npatient specific, time consuming and expensive. Scancell has developed its\nbreakthrough patent protected ImmunoBody® technology to overcome these\nlimitations.\n\nAn ImmunoBody® is a human antibody or fusion protein engineered to express\nhelper cell and CTL epitopes from tumour antigens over-expressed by cancer...